1-3 of 3
liposomal cytarabine-daunorubicin cpx-351
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Single-center experience with venetoclax combinations in patients with newly diagnosed and relapsed AML evolving from MPNs

Clinical Trials & Observations
Lucia Masarova, Courtney D. DiNardo, Prithviraj Bose, Naveen Pemmaraju, Naval G. Daver, Tapan M. Kadia, Helen T. Chifotides, Lingsha Zhou, Gautam Borthakur, Zeev Estrov, Marina Konopleva, Srdan Verstovsek
Journal: Blood Advances
Blood Adv (2021) 5 (8): 2156–2164.
https://doi.org/10.1182/bloodadvances.2020003934
Published: 2021
Includes: Supplemental data
Journal Articles

Older adults with newly diagnosed high-risk/secondary AML who achieved remission with CPX-351: phase 3 post hoc analyses

Clinical Trials & Observations
Tara L. Lin, David A. Rizzieri, Daniel H. Ryan, Gary J. Schiller, Jonathan E. Kolitz, Geoffrey L. Uy, Donna E. Hogge, Scott R. Solomon, Matthew J. Wieduwilt, Robert J. Ryan, Stefan Faderl, Jorge E. Cortes, Jeffrey E. Lancet
Journal: Blood Advances
Blood Adv (2021) 5 (6): 1719–1728.
https://doi.org/10.1182/bloodadvances.2020003510
Published: 2021
Includes: Supplemental data
Journal Articles

The role of targeted therapy in the management of patients with AML

Clinical Trials & Observations
Alexander E. Perl
Journal: Blood Advances
Blood Adv (2017) 1 (24): 2281–2294.
https://doi.org/10.1182/bloodadvances.2017009829
Published: 2017